V
VYNE Therapeutics Inc. (VYNE)
NCM – Real vaqt narxi. Valyuta: USD
0.66
-0.00 (-0.69%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
0.66
-0.00 (-0.69%)
Yopilishda: May 12, 2026, 4:00 PM EDT
VYNE Therapeutics Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, surunkali yallig'lanish va immunitet vositasida kechadigan kasalliklarni davolash uchun terapiyalarni ishlab chiqishga qaratilgan. Kompaniyaning asosiy dasturi repibresib gel (VYN201) bo'lib, u topikal qo'llaniladigan kichik molekulali pan-bromodomain va ekstra-terminal (BET) inhibitör yumshoq dori bo'lib, tizimli ta'sirini kamaytirish bilan ko'p va turli xil yallig'lanish hujayralari signalizatsiya yo'llarini o'z ichiga olgan kasalliklarni davolash uchun mo'ljallangan. Kompaniya shuningdek, immunitet vositasida kechadigan yallig'lanish holatlarini o'tkir nazorat qilish va surunkali boshqarish uchun 1b faza sinovida bo'lgan BD2-selektiv og'iz orqali qabul qilinadigan kichik molekulali BET inhibitör VYN202ni ishlab chiqadi. VYNE Therapeutics Inc. ilgari Menlo Therapeutics Inc. nomi bilan tanilgan va 2020 yil sentyabr oyida VYNE Therapeutics Inc. nomini o'zgartirgan. Kompaniya 2003 yilda tashkil etilgan va Nyu-Jersi shtatining Styuartsvill shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Darrell S. Rigel FAAD, M.D. | Consultant |
| Dr. Iain A. Stuart Ph.D. | Chief Scientific Officer |
| Mr. David T. Domzalski | CEO, President & Director |
| Mr. Tyler Zeronda CPA | CFO & Treasurer |
| Ms. Mutya Harsch J.D. | General Counsel, Chief Legal Officer & Company Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-28 | S-4/A | vyne-20251231xs4a.htm |
| 2026-03-31 | S-4 | vyne-20251231xs4.htm |
| 2026-03-11 | 8-K | tm268461d1_8k.htm |
| 2026-02-27 | 10-K | vyne-20251231.htm |
| 2026-01-30 | DRS | filename1.htm |
| 2026-01-30 | 425 | tm264541d2_425.htm |
| 2025-12-17 | 425 | tm2533624d2_425.htm |
| 2025-12-12 | 8-K | tm2533382d1_8k.htm |
| 2025-11-12 | ARS | tm2530688d2_ars.pdf |
| 2025-11-06 | 8-K | mnlo-20251106.htm |